Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Bristol Myers Squibb said Sunday it will acquire drugmaker Mirati Therapeutics in a deal worth up to $5.8 billion, adding to its oncology business portfolio. The company said it will pay $58 per share in cash. As part of the deal, Mirati stockholders will also receive one non-tradeable contingency value for each Mirati share held, potentially worth $12 per share in cash while representing an additional $1 billion of value opportunity, according to the announcement.
With multiple targeted oncology assets including Krazati, Mirati is another important step forward in our efforts to grow our diversified oncology portfolio and further strengthen Bristol Myers Squibb’s pipeline for the latter half of the decade and beyond," Bristol Myers Squibb CFO and CEO-elect Chris Boerner said in a statement.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Read more »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Read more »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Read more »
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion dealBristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Read more »
Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reportsBristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports
Read more »
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 BillionThe acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb’s best-selling products.
Read more »